Further Development Will Increase Confidence

Peter Poechlauer, innovation manager Pharma Services,  Patheon
Peter Poechlauer, innovation manager Pharma Services, Patheon

Originators discover new drug candidates by screening sub­stance libraries containing only a few milligrams per sub­stance. Many synthetic methods employed in library synthesis are not scalable: during further development, they have to be modified or redesigned to deliver quantities for further testing. At this point, custom development and manufacturing organizations (CDMOs) such as Patheon offer to perform the respective process development and manufacturing tasks. In this environment, flow chemistry provides various opportunities, for instance, to scale up even demanding synthetic steps without the need for a re-design, to control synthesis processes to deliver products with predictable quality at all required scales while the ultimately required production scale is still uncertain, to speed up process development through quick screening of reaction parameters, and to intensify processes, which reduces investment and variable, e.g. solvent and raw material costs.
Production of many APIs has moved to the East, freeing up conventional cGMP-rated manufacturing capacity in the West. This hampers decisions to invest in new technology developments that tend to reduce the utilization of this manufacturing capacity further.
In response to the growing number of newly developed APIs with a reduced volume per API the industry will shift towards concepts of manufacturing and quality assurance based on flow processes in flexible modular plants that are quickly reconfigured to supply the variety of small-volume products in the required quality and on short notice.
Further successful implementation of flow chemistry processes in cGMP manufacturing environments will increase confidence in this technology. It will convince manufacturers of APIs to consider developing flow processes or to team up with CDMOs with proven experience in this field.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
14.05.2025 • TopicsPharma

Pharma Outlook 2025

The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.

Photo
19.03.2025 • TopicsStrategy

The Future of Demand for Chemicals

The chemical industry is shifting to sustainability-related products, with demand growing 4.5 times faster than conventional ones. Companies must revise their market strategies to capitalize on this opportunity.